Cargando…

Probiotic triangle of success; strain production, clinical studies and product development

The successful development of probiotic foods and dietary supplements rests on three pillars; each with their specific challenges and opportunities. First, strain production; this depends on selecting the right strain with promising technological properties and safety profile. Further the manufactur...

Descripción completa

Detalles Bibliográficos
Autores principales: Forssten, Sofia D, Laitila, Arja, Maukonen, Johanna, Ouwehand, Arthur C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578568/
https://www.ncbi.nlm.nih.gov/pubmed/33049046
http://dx.doi.org/10.1093/femsle/fnaa167
_version_ 1783598394431766528
author Forssten, Sofia D
Laitila, Arja
Maukonen, Johanna
Ouwehand, Arthur C
author_facet Forssten, Sofia D
Laitila, Arja
Maukonen, Johanna
Ouwehand, Arthur C
author_sort Forssten, Sofia D
collection PubMed
description The successful development of probiotic foods and dietary supplements rests on three pillars; each with their specific challenges and opportunities. First, strain production; this depends on selecting the right strain with promising technological properties and safety profile. Further the manufacturing of the strain in a stable format at sufficiently high yield, following regulatory and customer requirements on culture media ingredients and other processing aids. The second pillar are the preclinical and clinical studies to document that the strain is a probiotic and exerts a health benefit on the host, the consumer. Especially when aiming for a regulator approved health claim, clinical studies need to be thoroughly performed; following appropriate ethical, scientific and regulatory guidelines. Finally, the probiotic will need to be incorporated in a product that can be brought to the consumer; a dietary supplement or a functional food. Because of the live nature of probiotics, specific challenges may need to be dealt with. Although experience from other strains is helpful in the process, the development is strain specific. Commercialisation and marketing of probiotics are strictly but differently regulated in most jurisdictions; defining what can and cannot be claimed.
format Online
Article
Text
id pubmed-7578568
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-75785682020-10-28 Probiotic triangle of success; strain production, clinical studies and product development Forssten, Sofia D Laitila, Arja Maukonen, Johanna Ouwehand, Arthur C FEMS Microbiol Lett Minireview The successful development of probiotic foods and dietary supplements rests on three pillars; each with their specific challenges and opportunities. First, strain production; this depends on selecting the right strain with promising technological properties and safety profile. Further the manufacturing of the strain in a stable format at sufficiently high yield, following regulatory and customer requirements on culture media ingredients and other processing aids. The second pillar are the preclinical and clinical studies to document that the strain is a probiotic and exerts a health benefit on the host, the consumer. Especially when aiming for a regulator approved health claim, clinical studies need to be thoroughly performed; following appropriate ethical, scientific and regulatory guidelines. Finally, the probiotic will need to be incorporated in a product that can be brought to the consumer; a dietary supplement or a functional food. Because of the live nature of probiotics, specific challenges may need to be dealt with. Although experience from other strains is helpful in the process, the development is strain specific. Commercialisation and marketing of probiotics are strictly but differently regulated in most jurisdictions; defining what can and cannot be claimed. Oxford University Press 2020-10-13 /pmc/articles/PMC7578568/ /pubmed/33049046 http://dx.doi.org/10.1093/femsle/fnaa167 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of FEMS. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Minireview
Forssten, Sofia D
Laitila, Arja
Maukonen, Johanna
Ouwehand, Arthur C
Probiotic triangle of success; strain production, clinical studies and product development
title Probiotic triangle of success; strain production, clinical studies and product development
title_full Probiotic triangle of success; strain production, clinical studies and product development
title_fullStr Probiotic triangle of success; strain production, clinical studies and product development
title_full_unstemmed Probiotic triangle of success; strain production, clinical studies and product development
title_short Probiotic triangle of success; strain production, clinical studies and product development
title_sort probiotic triangle of success; strain production, clinical studies and product development
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578568/
https://www.ncbi.nlm.nih.gov/pubmed/33049046
http://dx.doi.org/10.1093/femsle/fnaa167
work_keys_str_mv AT forsstensofiad probiotictriangleofsuccessstrainproductionclinicalstudiesandproductdevelopment
AT laitilaarja probiotictriangleofsuccessstrainproductionclinicalstudiesandproductdevelopment
AT maukonenjohanna probiotictriangleofsuccessstrainproductionclinicalstudiesandproductdevelopment
AT ouwehandarthurc probiotictriangleofsuccessstrainproductionclinicalstudiesandproductdevelopment